Journal of Endocrinological Investigation

, Volume 39, Issue 3, pp 277–283 | Cite as

The impact of oral contraceptives on cardiometabolic parameters

  • M. Farahmand
  • F. Ramezani TehraniEmail author
  • M. Rostami Dovom
  • S. Hashemi
  • F. Azizi
Original Article



There is much controversy regarding the use of oral contraceptive pills (OCPs) on cardiometabolic parameters, which is why this longitudinal population-based study was conducted to assess the impact of OCP use and its duration on cardiometabolic factors.


Of 5532 reproductive-aged participants of the Tehran lipid and glucose study, 3160 women who met our inclusion criteria were subdivided according to the duration of OCPs consumption into four sub-groups: (1) Non-users; (2) <11 month users; (3) 12–35 month users, and (4) ≥36 month users, and their cardiometabolic parameters were compared.


No statistical significant differences were observed between the cardiometabolic parameters of these sub-groups, after further adjustment for confounding factors including age, parity, and education, except for mean low-density lipoprotein-cholesterol which was significantly higher in women who used OCPs for >36 months in comparison to non-OCP users. The odds ratio of hypercholesterolemia was significantly higher in women who used OCPs for >36 months in comparison to non-OCP users; being 1.5 times higher than non-users (95 % CI 1.01–2.2).


Results showed that if used for less than 3 years, OCPs have no cardiometabolic effects.


Lipoproteins Cardiovascular risk factors Metabolic syndrome Hypertension Contraceptive pills Tehran lipid and glucose study (TLGS) 



We are indebted to all the study participants for the substantial time and effort contributed to this study. Acknowledgments are also due to the research staff at the (TLGS) Unit and personnel of the Research Endocrine Laboratory. The authors wish to thank Ms. N. Shiva for critical editing of English grammar and syntax of the manuscript.

Compliance with ethical standards

Conflict of interest

The authors declare that there are no competing interests and that the source of funding is independent of the objectives and results found in this study.

Ethical approval

Approval of the ethical committee of the research institute for endocrine sciences was obtained for the study, and written consents were obtained from all study participants.

Informed consent

The written inform consent was obtained from all individual participants included in the study.


  1. 1.
    ESHRE (2006) Hormones and cardiovascular health in women. Hum Reprod Update 12:483–497CrossRefGoogle Scholar
  2. 2.
    Mendelsohn ME, Karas RH (2005) Molecular and cellular basis of cardiovascular gender differences. Science 308(5728):1583–1587CrossRefPubMedGoogle Scholar
  3. 3.
    WHO (1998) Cardiovascular disease and steroid hormone contraception. Tech Rep Ser 877:89Google Scholar
  4. 4.
    Godsland IF, Crook D, Devenport M, Wynn V (1995) Relationships between blood pressure, oral contraceptive use and metabolic risk markers for cardiovascular disease. Contraception 52(3):143–149CrossRefPubMedGoogle Scholar
  5. 5.
    Fisch IR, Frank J (1977) Oral contraceptives and blood pressure. JAMA 237(23):2499–2503CrossRefPubMedGoogle Scholar
  6. 6.
    Cain MD, Walters WA, Catt KJ (1971) Effects of oral contraceptive therapy on the renin-angiotensin system. J Clin Endocrinol Metab 33(4):671–676CrossRefPubMedGoogle Scholar
  7. 7.
    Blum M, Zacharovich D, Gelernter I, Blum I (1988) Influence of oral contraceptive treatment on blood pressure and 24-hour urinary catecholamine excretion in smoking as compared with non-smoking women. Adv Contracept 4(2):143–149CrossRefPubMedGoogle Scholar
  8. 8.
    Spellacy WN, Birk SA (1972) The effect of intrauterine devices, oral contraceptives, estrogens, and progestogens on blood pressure. Am J Obstet Gynecol 112(7):912–919PubMedGoogle Scholar
  9. 9.
    Whitworth JA, Scoggins BA, Andrews J, Williamson PM, Brown MA (1992) Haemodynamic and metabolic effects of short term administration of synthetic sex steroids in humans. Clin Exp Hypertens A 14(5):905–922PubMedGoogle Scholar
  10. 10.
    Godsland IF, Crook D, Simpson R, Proudler T, Felton C, Lees B et al (1990) The effects of different formulations of oral contraceptive agents on lipid and carbohydrate metabolism. N Engl J Med 323(20):1375–1381CrossRefPubMedGoogle Scholar
  11. 11.
    Klaus JR, Hurwitz BE, Llabre MM, Skyler JS, Goldberg RB, Marks JB et al (2009) Central obesity and insulin resistance in the cardiometabolic syndrome: pathways to preclinical cardiovascular structure and function. J Cardiometab Syndr 4(2):63–71CrossRefPubMedGoogle Scholar
  12. 12.
    Regitz-Zagrosek V, Lehmkuhl E, Mahmoodzadeh S (2007) Gender aspects of the role of the metabolic syndrome as a risk factor for cardiovascular disease. Gend Med 4(Suppl B):S162–S177CrossRefPubMedGoogle Scholar
  13. 13.
    Hurwitz BE, Henry N, Goldberg RB (2009) Long-term oral contraceptive treatment, metabolic syndrome and measures of cardiovascular risk in pre-menopausal women: National Health and Nutrition Examination Survey 1999–2004. Gynecol Endocrinol 25(7):441–449CrossRefPubMedGoogle Scholar
  14. 14.
    Brinton EA (1996) Oral estrogen replacement therapy in postmenopausal women selectively raises levels and production rates of lipoprotein A-I and lowers hepatic lipase activity without lowering the fractional catabolic rate. Arterioscler Thromb Vasc Biol 16(3):431–440CrossRefPubMedGoogle Scholar
  15. 15.
    Azizi F, Rahmani M, Emami H, Mirmiran P, Hajipour R, Madjid M et al (2002) Cardiovascular risk factors in an Iranian urban population: Tehran lipid and glucose study (phase 1). Soz Praventivmed 47(6):408–426CrossRefPubMedGoogle Scholar
  16. 16.
  17. 17.
    Alberti KG, Eckel RH, Grundy SM, Zimmet PZ, Cleeman JI, Donato KA et al (2009) Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation 120(16):1640–1645CrossRefPubMedGoogle Scholar
  18. 18.
    Ford ES, Giles WH, Dietz WH (2002) Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey. JAMA 287(3):356–359CrossRefPubMedGoogle Scholar
  19. 19.
    Ford ES (2005) Prevalence of the metabolic syndrome defined by the International Diabetes Federation among adults in the U.S. Diabetes Care 28(11):2745–2749CrossRefPubMedGoogle Scholar
  20. 20.
    Merz CN, Johnson BD, Berga S, Braunstein G, Reis SE, Bittner V (2006) Past oral contraceptive use and angiographic coronary artery disease in postmenopausal women: data from the National Heart, Lung, and Blood Institute-sponsored Women’s Ischemia Syndrome Evaluation. Fertil Steril 85(5):1425–1431CrossRefPubMedGoogle Scholar
  21. 21.
    Coney P, Washenik K, Langley RG, DiGiovanna JJ, Harrison DD (2001) Weight change and adverse event incidence with a low-dose oral contraceptive: two randomized, placebo-controlled trials. Contraception 63(6):297–302CrossRefPubMedGoogle Scholar
  22. 22.
    Lello S, Vittori G, Paoletti AM, Sorge R, Guardianelli F, Melis GB (2007) Effects on body weight and body composition of a low-dose oral estroprogestin containing ethinyl estradiol 20 microg plus levonorgestrel 100 microg. Gynecol Endocrinol 23(11):632–637CrossRefPubMedGoogle Scholar
  23. 23.
    Watanabe RM, Azen CG, Roy S, Perlman JA, Bergman RN (1994) Defects in carbohydrate metabolism in oral contraceptive users without apparent metabolic risk factors. J Clin Endocrinol Metab 79(5):1277–1283PubMedGoogle Scholar
  24. 24.
    Kjos SL, Peters RK, Xiang A, Thomas D, Schaefer U, Buchanan TA (1998) Contraception and the risk of type 2 diabetes mellitus in Latina women with prior gestational diabetes mellitus. JAMA 280(6):533–538CrossRefPubMedGoogle Scholar
  25. 25.
    Guazzelli CA, Lindsey PC, de Araujo FF, Barbieri M, Petta CA, Aldrighi JM (2005) Evaluation of lipid profile in adolescents during long-term use of combined oral hormonal contraceptives. Contraception 71(2):118–121CrossRefPubMedGoogle Scholar
  26. 26.
    Wiegratz I, Lee JH, Kutschera E, Bauer HH, von Hayn C, Moore C et al (2002) Effect of dienogest-containing oral contraceptives on lipid metabolism. Contraception 65(3):223–229CrossRefPubMedGoogle Scholar
  27. 27.
    Cheung MC, Walden CE, Knopp RH (1999) Comparison of the effects of triphasic oral contraceptives with desogestrel or levonorgestrel on apolipoprotein A-I-containing high-density lipoprotein particles. Metabolism 48(5):658–664CrossRefPubMedGoogle Scholar
  28. 28.
    Kemmeren JM, Algra A, Grobbee DE (2001) Effect of second and third generation oral contraceptives on lipid metabolism in the absence or presence of the factor V Leiden mutation. J Intern Med 250(5):441–448CrossRefPubMedGoogle Scholar
  29. 29.
    Walsh BW, Schiff I, Rosner B, Greenberg L, Ravnikar V, Sacks FM (1991) Effects of postmenopausal estrogen replacement on the concentrations and metabolism of plasma lipoproteins. N Engl J Med 325(17):1196–1204CrossRefPubMedGoogle Scholar
  30. 30.
    Campos H, Sacks FM, Walsh BW, Schiff I, O’Hanesian MA, Krauss RM (1993) Differential effects of estrogen on low-density lipoprotein subclasses in healthy postmenopausal women. Metabolism 42(9):1153–1158CrossRefPubMedGoogle Scholar
  31. 31.
    Ritsch A, Kaser S, Volgger B, Abfalter E, Sturm W, Ganzer H et al (2002) Enhancement of cholesteryl ester transfer in plasma by hormone-replacement therapy. Metabolism 51(5):599–604CrossRefPubMedGoogle Scholar
  32. 32.
    Godsland IF (2004) Biology: risk factor modification by OCs and HRT lipids and lipoproteins. Maturitas 47(4):299–303CrossRefPubMedGoogle Scholar
  33. 33.
    Schaefer EJ, Foster DM, Zech LA, Lindgren FT, Brewer HB Jr, Levy RI (1983) The effects of estrogen administration on plasma lipoprotein metabolism in premenopausal females. J Clin Endocrinol Metab 57(2):262–267CrossRefPubMedGoogle Scholar
  34. 34.
    Jones DR, Schmidt RJ, Pickard RT, Foxworthy PS, Eacho PI (2002) Estrogen receptor-mediated repression of human hepatic lipase gene transcription. J Lipid Res 43(3):383–391PubMedGoogle Scholar
  35. 35.
    Carr BR (1998) Uniqueness of oral contraceptive progestins. Contraception 58(3 Suppl):23S–27S quiz 67S CrossRefPubMedGoogle Scholar
  36. 36.
    Gaspard U, Endrikat J, Desager JP, Buicu C, Gerlinger C, Heithecker R (2004) A randomized study on the influence of oral contraceptives containing ethinylestradiol combined with drospirenone or desogestrel on lipid and lipoprotein metabolism over a period of 13 cycles. Contraception 69(4):271–278CrossRefPubMedGoogle Scholar
  37. 37.
    Tehrani FR (2006) Contraception use behavior of Iranian women (5 selected provinces of Iran), Iran. Report No.: final research project reportGoogle Scholar

Copyright information

© Italian Society of Endocrinology (SIE) 2015

Authors and Affiliations

  • M. Farahmand
    • 1
  • F. Ramezani Tehrani
    • 1
    Email author
  • M. Rostami Dovom
    • 1
  • S. Hashemi
    • 1
  • F. Azizi
    • 2
  1. 1.Reproductive Endocrinology Research Center, Research Institute for Endocrine SciencesShahid Beheshti University of Medical SciencesTehranIslamic Republic of Iran
  2. 2.Endocrine Research Center, Research Institute for Endocrine SciencesShahid Beheshti University of Medical SciencesTehranIslamic Republic of Iran

Personalised recommendations